bucolome manufacturers
- bucolome
-
- $1.00
-
2026-02-02
- CAS:841-73-6
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50tons
|
| | bucolome Basic information |
| Product Name: | bucolome | | Synonyms: | bucolome;Bucolomum [INN-Latin];1-Cyclohexyl-5-butyl-2,4,6-trioxoperhydropyrimidine;2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-butyl-1-cyclohexyl-;5-Butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine;5-Butyl-1-cyclohexyl-2,4,6-trioxoperhydroxyprimidine;5-Butyl-1-cyclohexylbarbituric acid;5-n-Butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine | | CAS: | 841-73-6 | | MF: | C14H22N2O3 | | MW: | 266.34 | | EINECS: | 2126661 | | Product Categories: | | | Mol File: | 841-73-6.mol |  |
| | bucolome Chemical Properties |
| Melting point | 84° | | Boiling point | bp0.8 185-187° | | density | 1.0807 (rough estimate) | | refractive index | 1.5110 (estimate) | | pka | 5.71±0.40(Predicted) | | form | Solid | | color | White to off-white |
| | bucolome Usage And Synthesis |
| Uses | Bucolome is a CYP2C9 inhibitor, used as an uricosuric agent or anti-inflammatory agent. | | Definition | ChEBI: 5-butyl-1-cyclohexylbarbituric acid is a member of barbiturates. | | IC 50 | CYP2 | | References | [1] Takahashi H, et al. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. Drug Metab Dispos. 1999 Oct;27(10):1179-86. PMID:10497145 |
| | bucolome Preparation Products And Raw materials |
|